Enquirer: Venture capital firm relocates to 1819 Innovation Hub
Orange Grove Bio plans to partner with UC to cultivate biotech landscape
A venture capital firm is relocating its headquarters from New York City to the University of Cincinnati 1819 Innovation Hub, the Cincinnati Enquirer reported.
Orange Grove Bio, which invests mainly in therapeutic drug companies, cited several reasons for moving to Cincinnati including proximity to other research hubs in the Midwest, the cost of living and quality of life in the area, said Ryan Fox, Orange Grove's chief business operations officer.
In Cincinnati, Orange Grove will partner with UC to help cultivate “the increasingly robust Cincinnati biotech landscape.”
The company plans to start with six to eight employees in Cincinnati. It expects to hire as many as 30 to 50 employees over the next several years, Fox said.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's undergraduate, graduate and medical students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.